| Similar Articles |
|---|
 |
The Motley Fool
June 15, 2007
Brian Lawler |
AOB Supplements Itself American Oriental Bioengineering makes an acquisition. Investors, with privately owned companies, it can be hard to find good information on their businesses, so it's tough to make any evaluation as to what AOB is getting with this acquisition.   |
The Motley Fool
June 10, 2008
Brian Lawler |
Buy Back Shares, Then Issue More? Investors marvel at what seems like temporary financial schizophrenia from American Oriental Bioengineering. |
The Motley Fool
November 11, 2008
Brian Orelli |
AOB Is A-OK Growing through acquisitions seems to be working. |
The Motley Fool
December 6, 2010
Travis Hoium |
Battery Maker Sucker Punches Investors A dilutive share offering should give investors shivers. |
The Motley Fool
March 10, 2009
Brian Orelli |
So Much Potential, So Little Growth In its quest to become the Johnson & Johnson of China, this purveyor of traditional Chinese medicine has been growing through acquisitions, but has paid for them through dilutive stock offerings. |
The Motley Fool
August 10, 2009
Brian Orelli |
This Volatile Stock Has Growth Potential China is scary. AOB? Scarier. |
The Motley Fool
November 11, 2010
Travis Hoium |
This Chinese Stock Is in a Rut R&D isn't bringing a turnaround for American Oriental Bioengineering. |
The Motley Fool
January 15, 2009
Tim Hanson |
One Heckuva Cheap Stock Would you pay nine times earnings to buy shares of a company growing 48% annually? What about six times earnings for a company growing by 50%? How about six times for a company growing at greater than 80% per year? Take a look at three such Chinese stocks. |
The Motley Fool
April 2, 2007
Brian Lawler |
American Oriental's Political Twists Health products distributor American Oriental Bioengineering announces new pricing rules for its top product. Investors, take note. |
The Motley Fool
February 25, 2008
Brian Lawler |
Supplements Take a Hit The leaders of the company which produces the supplement Enzyte are convicted of deceptive advertising. It was allowed to do this because the FDA takes the opposite approach to supplement producers that it does for pharmaceutical drugmakers. |
The Motley Fool
September 22, 2006
Brian Lawler |
The Truth About Dietary Supplements The real issue here is not about one possibly corrupt supplement company -- it's about customers not knowing that the U.S. supplement industry isn't regulated the way pharmaceutical companies are. |
The Motley Fool
April 7, 2008
Mac Greer |
Fool Video: 3 Stocks Ready to Rock, Apple's Sweet Music, and China's Investing Remedy Will the music last for Apple's iTunes, or will Microsoft's Zune finally find its rhythm? Is American Oriental Bioengineering the right medicine for investors? These questions and others are discussed in this video. |
The Motley Fool
October 11, 2010
Travis Hoium |
AOB Shares Popped: What You Need to Know Shares of American Oriental Bioengineering rose 10% in intraday trading on unusually high volumes. |
The Motley Fool
March 5, 2009
Brian Orelli |
5 Stocks to Benefit From China's Health-Care Plan Same idea, different country. |
The Motley Fool
July 11, 2007
Brian Lawler |
Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note. |
The Motley Fool
February 2, 2009
Tim Hanson |
This Is Why I'll Make Money in China But will you? |
The Motley Fool
January 12, 2009
Brian Orelli |
Trust Management or Don't Buy American Oriental Bioengineering, purveyor of traditional Chinese medical products, bought a $70 million building to use as a "Convention and Training Center," and investors aren't happy about it. |
The Motley Fool
July 1, 2010
Tim Hanson |
Can You Trust Chinese Companies? Yes. And no. |
The Motley Fool
May 23, 2008
Mac Greer |
Fool Video: Buffett Buys China, the Ultimate Dividend Stock, and the Next Starbucks? Three Chinese stocks for Buffett, one big dividend stock, and the future of Jamba are discussed in this video. |
The Motley Fool
August 27, 2009
Brian Orelli |
The List You Have to Be On Good for you if your company's products made the cut in China. This sounds like a growth opportunity for American Oriental Bioengineering and anyone else who can get a place on the list. |
Financial Advisor
July 6, 2010 |
Innovative Alternative Strategies Conference Supplement 2010 The supplement to the Innovative Alternative Strategies Conference is attached. |
The Motley Fool
July 13, 2010
Jordan DiPietro |
Chinese Small Caps You Can Actually Buy Finding Chinese stocks on U.S. indexes can be difficult, so here's a start. |
The Motley Fool
February 26, 2009
Brian Orelli |
Big Blue Struts Its Stimulus Stuff The company announces that it had signed up four hospital groups in the U.S. to use its electronic medical records systems, after the stimulus bill contained $19 billion in grants and incentives to encourage doctors and hospitals to invest in electronic medical records. |
The Motley Fool
August 5, 2009
Alex Dumortier |
Will China's Accounting Cause a U.S. Stock Correction? Are China's national accounts accurate, or is it manufacturing GDP statistics in order to support the idea that it is floating above the global recession? These questions have troubling implications for U.S. investors. |
